A panel of outside advisers from the United States Food and Drug Administration (FDA) voted overwhelmingly in favor of supporting the emergency use of Pfizer Inc.’s coronavirus vaccine, paving the way for the agency to authorize the injection in a nation that has lost more than 285,000 lives to COVID-19.
The committee voted 17-4 that the known benefits of the vaccine, developed by Pfizer with Germany’s BioNTech, outweighed the risks in adults 16 years of age and older after receiving the injection. One panel member abstained.
.
